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Summary: In two children exhibiting the clinical symptoms of fucosidosis, the diagnosis was biochemically ascer-
tained by the demonstration of a profound - ,-fucosidase deficiency in cultured skin fibroblasts. The non-dialysed
urines of these fucosidosis patients were separated into two fractions by chromatography on Biogel P-2. The first
fraction containing the glycosaminoglycans was further fractionated on Dowex 1 X 2 by stepwise elution with in-
creasing NaCl concentrations. Keratan sulfate-chondroitin sulfates attached to the same peptide core were assayed
and characterised mainly in the fractions eluted with 1.25, 1.5, 2.0 and 3.0 mol/1 NaCl. Whereas the excretion of
normal children of the same age was found to be 0.77 /imol gjucosamine equivalents per day in the 2 mol/1 and
3 mol/1 NaCl fraction, the two patients excreted 6.7 (M. C.) and 3.5 (M. S.) /zmol glucosamine equivalents per day,
respectively. Since keratan sulfate contains -fucose at the non-reducing terminal, this increase in excretion of long
chain keratan sulfate in fucosidosis could result from impaired degradation of keratan sulfate, due to the a-fucosi-
dase deficiency.
Erhöhte Ausscheidung von Keratansulfat im Urin bei der Fucosidose
Zusammenfassung: Bei zwei Kindern mit dem klinischen Bild einer Fucosidose wurde die Diagnose durch den Nach-
weis eines - ,-Fucosidasemangels in kultivierten Hautfibroblasten biochemisch bestätigt. Die nicht dialysierten
Urine dieser Fucosidose-Patienten wurden durch Chromatographie an Biogel P-2 in zwei Fraktionen getrennt. Die
höher molekulare Fraktion, welche die Glykosaminoglykane enthielt, wurde weiterhin an Dowex 1 X 2 durch Elu-
tion mit ansteigenden NaCl-Konzentrationen getrennt. Hauptsächlich in den Fraktionen, die mit 1,25 mol/1,
1,5 mol/1, 2,0 mpl/1 und 3,0 mol/1 NaCl eluiert wurden, haben wir Keratansulfat-Chondroitinsulfate bestimmt und
charakterisiert, die denselben Peptidcore besitzen. Während die normale Kefatansulfatausscheidung gleichaltriger
Kinder in der 2 und 3 mol/1 NaCl-FraktiPn einen Mittelwert von 0,77 /miol Glucosamin-äquivalente pro Tag auf-
weist, wurden vom ersten Patienten 6,7 und vom zweiten Patienten 3,5 /imol Glucosaminäquivalente pro Tag ausge-
schieden. Da Keratansulfat am nicht-reduzierenden Ende -Fucose enthält, fuhren wir diese vermehrte Ausscheidung
von langkettigen Keratansulfaten beim Enzymdefeict der c^Fucpsidase auf den unvollständigen Abbau des Keratan-
sulfats zurück.
introduction in the time of onset and in phenotype (1,2). Van Hoof
„ . , , , &#0rs demonstrated a deficiency of the lysosomal
Fucosidosis * an inborn error pf complex c^bphycJrate ^y^ ^.fucosidase (EC 3^L51) ^  liver and other
metabolism, first described by Durand et al. m 1966
 tissues of fucosidosis patients> whereas other lysosomal
(1), By now, more than 20 patients have been observed
 h drolases Were normal or even increased (3, 4).
allowing the definition of a clinical picture exhibiting
progressive neurodegeneration, mental retardation«, Due to the enzymatic defect, there is an abnormal
prganpmegaly, and skeletal abnormalities (1, 2). A accumulation of fucose-containing oligosaccharides
severe type of the disease (type I) has been differentiated and glycolipids in the liver of such patients (4, 5).
from a less severe form (type II) based on differences Conclusive evidence for a defect in the catabolism of
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glycosaminoglycans, however, has been lacking so far.
In keratan sulfate, a substantial part of the poly-
saccharide chains contain a fucosyl residue at the non-
reducing terminus, as found by gas chromatography/
mass spectrometry-studies after permethylation of
keratan sulfates from bovine cornea and human rib
cartilage (6), as well as human knee joint cartilage and
bovine tracheal cartilage (7, 8). It was therefore of
interest, to investigate the keratan sulfate excretion in
the urine of patients with fucosidosis.
Materials and Methods
Determination of lysosomal enzyme activities
in cultured skin fibroblasts
Fibroblast cultures from fucosidosis patients M. S. (type I;
8 years of age; patient described by Voelz et al. (8a)) and M. C.
(type II; 11 years of age) were established and maintained
according to published procedures (9). The fibroblasts were
homogenized, and the activities of lysosomal enzymes deter-
mined, as described previously (10, 11).
Separation, isolation, and determination
of urinary glycosaminoglycans
Chromatography on Bio Gel P-2 and Dowex 1x2
Twenty-four hour urine samples were collected from fucosidosis
patients M. S. and M. C., and from 7 healthy children, and kept
at - 20 °C until processed. The specimens were concentrated
by rotary evaporation at 40 °C to between 1/4 and 1/10 of the
original volume, adjusted to an ethanol concentration of
100 ml/1 and subsequently chromatographed on a column of
Bio Gel P-2 (4.8 X 80 cm; fig. 1). The column was equilibrated
and eluted with ethanol/water (volumes, 100 ml + 900 ml) and
20 mi-fractions were collected. Uronic acid determination
(carbazole method) of each fraction showed the presence of
two peaks, the first appearing in the excluded volume and
representing the glycosaminoglycans, and a second retarded
peak consisting mainly of glycosaminoglycan-free uronides.
Whereas the fractions of the first peak yielded both glucosamine
as well as galactosamine upon hydrolysis, no hexosamines were
found in the second peak. The glycosaminoglycan fractions
(1. peak) were pooled, concentrated to approximately 100 ml
and loaded onto a Dowex 1 X 2 column (2 X 20 cm; Cl^-form),
which was then eluted stepwise with 200 mi-portions of 0.15,
0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 2.00, and 3.00 mol/1 NaCl.
The eluate was collected in 7.5 mi-fractions, which were analyzed
for their uronic acid content (fig. 2). Uronic acid-positive frac-
tions of each elution step (as identified by its conductivity)
were combined, concentrated as much as possible, brought to
an ethanol concentration of 100 ml/1, and then desalted
individually on a Bio Gel P-2 column, which was equilibrated
and eluted with ethanol/water (volumes, 100 ml + 900 ml).
The desalted glycosaminoglycan fractions (figs. 1 and 2) were
then analyzed for their constituents as described in the follow-
ing paragraph.
Analyses of constituents
Uronic acid was determined using the carbazole reaction of
Dische (12) as modified by Bitter & Muir (13). The galactose
content of the glycosaminoglycans was measured both enzyn>
atically with galactose denydrogenase (14), and by gas chromato-
graphy using the alditol acetate method (15), after prior hydro-
lysis of the samples with 1 rnol/1 HC1 at 105 °C for 3 h. Fucose,
mannose, and xylose were also determined by gas chromato-
graphy using the alditol acetate method. Sulfate was determined
turbidimetrically as BaSO4 (16). Glucosamine and galactosamine,
together with amino acids* were determined after hydrolysis
for 15 hours in 3 mol/1 HCl at 105 °C using an amino acid
analyzer (TSM, Technicon). No difference in the yield of amino
acids was found on hydrolysis for 20 hours in 6 mol/1 HCl at
105 °C. The elution program of the analyzer was modified in
such a way as to allow the determination of glucosamine,
galactosamine, hydrpxyprolme, and other amino acids in less
than 2l/2 hours (17). N-sulfate was determined according to
Lagunoff et zl. (18).
Electrophoresis
The glycosaminoglycan fractions obtained by Dowex chromato-
graphy were subjected to electrophoresis on cellulose acetate
in 0.05 mol/l barium acetate buffer, pH 7.0. The duration of
electrophoresis was 40 min at a potential gradient of 20 V/cm.
Results
The results of the determinations of lysosomal hydro-
lases in the skin fibroblasts of patients M. S. and
M. C. are shown in table 1. There was a profound
deficiency of α-Ζ,-fucosidase activity in both patients,
whereas the activities of jS-D-glucuronidase, /3-Z>-glucosi-
dase, a-/)-galactosidase, a-N-acetyl-Z)-glucosaminidase,
|3-N-acetyl-/?-glucosaminidase, and a-Z)-mannosidase
were within normal limits. The activities of arylsulfatase
A and acid phosphatase, and in one case also of -D-
Urine
Chromatography on Biogel P-2
_L
Fraction I Fraction II
Chromatography on Dowex 1 X 2
Elution with increasing concentrations of NaCl (mol/1)
H2O 0.15 1.25 1.5 3.0
Fig. 1. Separation and isolation of urinary glycosaminoglycans.
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Tab. 1. Enzyme activities (U/g protein) in fibroblasts of 6 nor-
mal children and 2 patients with fucosidosis.
0£-L-Fucosidase
(EC 3.2.1.51)
0-£>-Galactosidase
(EC 3.2.1.23)
0-jD-Glucuronidase
(EC 3.2.1. 31)
0-jD-Glucosidase
(EC 3.2.1.21)
<*-D-Gaiactosidase
(EC 3.2.1.22)
oc-N-Acetyl-^-glucos-
aminidase (EC 3.2.1.50)
0-N-Acetyl-/}-glucos-
aminidase (EC 3.2.1.30)
α-jD-Manno sidase
(EC 3.2.1.24)
Arylsulfatase A
(EC 3.1.6.1)
Acid phosphatase
(EC 3.1.3.2)
Normal
children
mean value
(min.-max.
values)
0.897
(0.317-1.32)
7.17
(5.60-9.53)
3.48
(1.80-6.05)
0.571
(0.322-1.08)
1.92
(1.23-2.37)
0.132
(0.073-0.190)
137
(104-211)
1.20
(0.691-1.62)
8.42
(4.22-12.0)
12.5
(6.96-15.3)
Patient
M.C.
0.072
8.32
2.87
1.22
1.62
0.102
124
1.47
12.1
21.8
Patient
M.S.
0.068
14.9
4.85
1.06
2.06
0.149
184
1.29
18.1
24.3
galactosidase, were somewhat elevated. These data
clearly confirmed the diagnosis of fucosidosis in these
two patients.
The urinary gjycosaminoglycans were isolated by first
subjecting the urine concentrates to chromatography
on Bio Gel P-2. The glycosaminoglycans, which appeared
in the excluded volume of the column, were thus sepa-
rated from low molecular weight uronides, e. g. phenolic
glucuronides, which were retarded on the gel. The
purified glycosaminoglycans were subsequently frac-
tionated on a column of Dowex 1 X 2 using NaCl solu-
tions of increasing molarity (fig. 2). As indicated by
the analysis of the gjycosaminoglycan constituents
(tab. 2) arid by electrophoretic analysis using authentic
gjycosarriinoglycan standards (not shown), most of the
chondroitin sulfates, as well as dermatan sulfate arid
heparan sulfate, were found in the 1.25 and 1.5 rripl/l
1.5
3mol/l NaCl
20 30
Fraction number
Fig. 2. Chromatography of the urinary glycosaminoglycans from
a fucosidosis patient on Dowex 1x2. The column was
eluted with NaCl of increasing molarity.
NaCl fractions. The 2.0 and 3.0 mol/1 NaCl fractions,
however, contained keratan sulfate as a copolymer
with variable amounts of chondroitin-4- and -6-sulfates,
and with dermatan sulfate.
In 7 healthy children from 6 to 12 years of age, the
sum of the keratan sulfate contents of the 2.0 and
3.0 mol/1 NaCl fractions ranged from 0.23 to
1.18 μπιοί glucosamine equivalents per day (mean
value 0.77 ± 0.29), as compared to values of
6.7 μπιοΐ/day in fticosidosis patient M. C., and
3.5 /imol/day in patient M. S., as shown in table 2 and
figure 3. Also in the 2.0 and 3.0 mol/1 NaCl fractions
there was an increase in the galactosaminoglycans
chondroitin-4- and -6-sulfates, and in dermatan sulfate,
which are thought to be linked to the same peptide
core as keratan sulfate. Thus, there were 6.4 μπιοί
galactosamine equivalents per day in patient M. C. and
3.1 μπιοί galactosamine equivalents per day in patient
M. S., as compared to a value of 1.26 ± 0.91 μηιοΐ/day
(range 0.23-2.08) in healthy children (Table 2, Fig. 3).
Tab. 2. Analyses of constituents of glycosaminoglycan fractions obtained by Dowex chromatography of urines from 2 fucosidosis
patients and 2 controls. The "3.0 mol/1" fraction represents the sum of the 2.0 and 3.0 mol/1 NaCl fractions. Values are
given as μπιοί per day; n. d. = not determined.
Patient M. C.
1.25 mol/1 1.5 mol/1 3.0 mpl/1
Patient M. S.
1.5 mol/1 3.0 mol/1
normal children
1.5 mol/1 3.0 mol/1
'Glucosamine
Galactosamine
Uronic acid
Galactose
Sulfate
4.0
3.5
6.3
1.9
4.6
2.7
14.4
17.1
3.8
12.3
6.7
6.4
6.4
n.d.
12.8
1.6
3.1
2.6
1.5
4.2
2.0
7.3
6.7
2.1
8.4
3.5
3.1
2.2
3.5
7.3
1.0
7.7
9.4
2.1
8.9
2.2
20.5
24.3
5.0
27.2
0.82
0.22
0.28
n. d.
1.2
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Fig. 3. Keratan sulfate (D) and chondroitin sulfate (Θ) contents
of the combined 2.0 and 3.0 mol/1 NaCl fractions obtained
by Dowex chromatography from the urines of 7 healthy
children and two patients with fucosidosis.
Therefore, keratan sulfate excretion in the two fucosi-
dosis patients amounted to 8.7 and 4.5 times that of
the mean value of the control group; the galactosamino-
glycan excretion was also markedly higher than the
upper limit of the controls.
Cellulose acetate electrqphoresis of the 2.0 and 3.0 mol/1
NaCl keratan sulfate fractions showed them to be homo-
geneous, with a mobility identical to that of chondroitin
sulfate-keratan sulfate copolymers from tracheal
cartilage. In patient M. C., the fucose and mannose
contents of these fractions were 0.6 and 0.8 μπιοΐ/day,
respectively. The major amirio acids in the 2.0 and
3.0 mol/1 NaCl fractions were aspartic acid, glutamic
acid, threonine, and serine.
Discussion
Previous investigations of urinary keratan sulfate excre-
tion have frequently been incomplete, as chemical
characterization of this compound was not attempted.
In addition, such studies were hampered by method-
ological problems. Thus, the commonly used cetyl-
pyridinium chloride procedure for precipitating the
urinary glycosaminoglycans may lead to erroneous
results due to the coprecipitetion of sialic acid-contain-
ing glycoproteins. Furthermore, the use of this proce-
dure may lead to an incomplete precipitation of kera-
tan sulfate at higher electrolyte concentrations, or to
a loss of short-chain keratan sulfate. Another source
of error involves dialysis of the sample, leading to .a
Protein-Asparagine—Protein
N-Acet y 1-glu co samine
Mannose
Mannose
Galactose—sulfate
N-Acetyl-glucosamine-sulfate
Galactose
N-Acetyl-glucosamine-sulfate
j3-Aspartylglucosamine-amidohydrolase
-^ 5 Marinosidase
-Galactosidase
-KS-6-sulfatase
- KS-N-Acetylglucosaminidase
KS^6-sulfatase
KS-Galactosidase
- KS-N-Acetylglucosaminidase
-KS-6rsulfatase
-a-Fucosidase
Fucose
Fig. 4. Postulated structure of the polysaccharide chains of proteokeratan sulfate, and the catabolic block in fucosidosis (·)
KS = keratan sulfate
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loss of short-chain polysaccharides. It was therefore
desirable to develop a procedure for the quantitation
of keratan sulfate which would be free of these dis-
advantages.
By using Bio Gel P-2 chromatography, short-chain
keratan sulfates are quantitatively recovered, yet
completely separated from low molecular weight
glucuronides. The subsequent chromatography on
Dowex 1 X 2 then allows a further fractionation of
the glycosaminogjycans. Thus, 0.5 mol/1 NaCl elutes
hyaluronate and chondroitin, or chondroitin sulfate
with a low degree of sulfation. The fractions from
0.75 to 1.5 mol/1 NaCl encompass the overlapping
elution profiles, in that order, of heparan sulfate,
chondroitin-4- and -6-sulfates, and dermatan sulfate.
The last steps, using 2.0 and 3.0 mol/1 NaCl, elute
keratan sulfate-chondroitin sulfate complexes,
whose polysaccharide chains have a common peptide
core. Whereas in the 2.0 mol/1 NaCl fraction the
copolymers contain more chondroitin sulfate than
keratan sulfate, the reverse is found in the 3.0 mol/1
NaCl fraction. Both fractions also contain the neutral
sugars typical for keratan sulfate: mannose, which is
localized in the linkage region between polysaccharide
chain and protein core, and fucose, which forms a
substantial part of the non-reducing terminus of the
keratan sulfate chains (6, 7,8). The amino acids
aspartic acid, glutamic acid, threonine, and serine,
which dominate in these two fractions, point to the
presence of the peptide core typical of keratan sulfate,
the chondroitin sulfates, and dermatan sulfate.
At present, we are lacking detailed studies concerning
the role of α-Ζ,-fucosidase in the degradation of keratan
sulfate. It is likely, however, that keratan sulfate is
catabolized sequentially by exoglycosidases and sulfa-
tases. Using lysosomal enzymes from rabbit kidney, we
were able to achieve such a degradation of the keratan
sulfate polysaccharide chain (19). The complete enzym-
atic degradation of keratan sulfate by a multi-enzyme
system from Charonia Lampas has recently been
demonstrated (20).
Glycoproteins with a terminal fuc se on their carbo-
hydrate chains have been described by several authors.
Thomas & Winzler isolated a glycopeptide from erythro-
cyte membranes exhibiting close structural resemblance
to keratan sulfate (21). The oligosaccharide chains of
this glycopeptide were linked to the peptide moiety via
aspartyUN-acetylglucpsamine and three m nriosyl
residues, as in the keratan sulfate of the cornea. The
sequential digestion of this glycopeptide with purified
rieuraminidase, α-Ζ,-fucosidase, 0-/)*galactosidase, and
jS-N-acetyl-Z^-glucosaniimdase led to its complete degrada-
tion and structural elucidation, one of the oligo-
saccharide chains having the sequence Fuc-Gal-GlcNAc.
Tsay and colleagues isolated a decasaccharide from the
urine of a fucosidosis patient with the structure Fuc
(a 1 ->2) Gal (0 l ->4) GlcNAc ( l ->2)Man
[Fuc(a 1 -> 2) Gal (β 1 ·+ 4) GlcNAc ( l -> 2) Man]
(a 1 -*> 3/6) Man ( l -» 4) GlcNAc, which closely
resembles the structural elements of keratan sulfate
(22). From the liver of a patient with GM rganglio-
sidosis type I, Callahan et al. isolated a polysaccharide
containing galactose, hexosamine and fucose, which
was chemically similar to undersulfated keratan suifate
of human cartilage (23). Its accumulation in the
patient's liver was thought to be due to the genetic
deficiency of 0-galactosidase.
A raised keratan sulfate excretion was also reported
in some cases of achondroplasia, rheumatoid arthritis
and dermatomyositis (24). An excessive keratan
sulfaturia is found in Morquio disease (mucopoly-
saccharidosis type IV). As discussed by Ginsberg et al.
(25), the increased keratan sulfate excretion in Mor-
quio disease may be caused by the following enzymatic
defects:
1. N-acetylgalactosamine-6-sulfate sulfatase, classical
Morquio, mucopolysaccharidosis type IVA;
2. 0-galactosidase, mild Morquio, mucopolysacchari-
dosis type IVB;
3. N-acetylglucosamine-6-sulfate sulfatase,Morquio·
Sanfilippo intermediate, which might occupy the
vacant position V ofMcKusick's classification.
Our results suggest that the increased excretion of
keratan sulfate in fucosidosis is due to the mechanism
depicted in figure 4. The α-fucosidase deficiency leads
to a block in the degradation of those keratan sulfate
chains which contain a terminal fucose residue. It is
unlikely, however, that the catabolism of all of the kera-
tan sulfate chains is similarly impaired, as part of the
chains terminate in neuraminic acid, instead of fucose
(6). Our finding that the keratan sulfate excreted in
fucosidosis appears as a copolymer with chondroitin
and dermatan sulfates is surprising, as these latter poly-
saccharides are not known to contain fucosyl residues
and might therefore be expected to be degraded in-
dependently of the keratan sulfate chains. Further work
is needed to clarify this point.
By analogy with the genetic mucopolysaccharidoses, it
is tempting to speculate that the skeletal abnormalities
found in patients with fucosidosis are caused by an
impaired keratan sulfate catabolism.
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